Therefore, this approach could integrate diagnostic oncology more closely with outcome-oriented clinical decisions by increasing the survival of BC patients with sdMTSs (T1-3N0-3M0 and ER/PR/HER2/Ki-67 subtypes). This evidence concerns the gene PGR and breast cancer.